Changes in the gut microbiota have been linked to obesity and type 2 diabetes, and intestinal bacteria have been shown to influence gut permeability, systemic inflammation levels and host metabolism. Akkermansia muciniphila, the dominant commensal bacterium in the intestinal mucus layer, has received particular attention because its abundance is inversely correlated with body mass in mice and humans. A study now shows how this bacterium modulates the intestinal barrier and metabolic functions, and thus might control obesity and associated metabolic diseases.
Mice fed a high-fat diet have an altered gut microbiota, including reduced numbers of A. muciniphila and higher blood concentrations of lipopolysaccharide. This condition of metabolic endotoxaemia has been implicated in low-grade inflammation and insulin resistance. To test whether the therapeutic administration of A. muciniphila could reverse these changes, mice on a high-fat diet received live or heat-killed bacteria orally for 4 weeks. Those administered live bacteria exhibited low levels of blood lipopolysaccharide, body fat and plasma glucose, similar to levels in non-obese mice receiving a control diet; by contrast, heat-killed bacteria had no therapeutic effect. Furthermore, treatment with live A. muciniphila stimulated the expression of genes involved in adipocyte differentiation, lipogenesis and lipid oxidation in visceral fat depots, indicating improved adipose tissue metabolism. Two mechanisms were proposed to link A. muciniphila in the intestine with favourable metabolic changes in the whole body: restoration of the intestinal barrier, including the mucus layer and the underlying epithelium that have been damaged by the high-fat diet, and modulation of the intestinal endocannabinoid system, which consists of lipid mediators that control barrier function, inflammation and glucose homeostasis. Indeed, in mice fed a high-fat diet, A. muciniphila restored the mucus layer back to its normal thickness and induced the production of the lipid mediators 2-arachidonoylglycerol, 2-palmitoylglycerol and 2-oleoylglycerol.
Taken together, these results indicate that A. muciniphila can normalize the intestinal barrier to reverse the diet-induced pathological changes that mediate metabolic diseases such as obesity and type 2 diabetes. Notably, supplementing the high-fat diet of the mice with oligofructose, which is used as a prebiotic to regulate the gut microbiota in humans, increased intestinal A. muciniphila numbers and had the same beneficial effects as direct administration of the bacterium. It remains to be tested whether the same holds true in humans. Obesity and type 1 diabetes are associated with lower numbers of A. muciniphila in humans; however, a recent metagenomic study found that some A. mucini phila genes are enriched in type 2 diabetes, maybe owing to confounding factors such as medication.
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